BACKGROUND AND OBJECTIVE: Women with multiple sclerosis (MS) who intend to get pregnant are often advised to discontinue disease modifying therapy (DMT) prior to conception. This recommendation is not based on medical evidence and may interfere with disease control by immunomodulatory drugs. The present study was designed to help discuss the effect of DMT for MS on pregnancy and on disease course. PATIENTS AND METHODS: Retrospective data from 152 pregnancies of 132 women with MS were collected by the physician in charge of the case. All data were entered into a specific file for qualitative and quantitative statistical analysis. RESULTS: From the total group of patients, 89 pregnancies occurred without any exposure to MS drugs, while 61 pregnancies occurred with at least eight weeks of exposure to MS immunomodulatory drugs. The rate of obstetric and neonatal complications was similar in both groups, except for the newborn weight and height which was smaller for mothers receiving medications. Mothers' post-delivery relapse rate and EDSS scores in the follow-up period were significantly higher in the absence of treatment. CONCLUSION: It is possible that, with further such supportive data, international guidelines on MS treatment in young women who intend to get pregnant may need to be revised.
BACKGROUND AND OBJECTIVE:Women with multiple sclerosis (MS) who intend to get pregnant are often advised to discontinue disease modifying therapy (DMT) prior to conception. This recommendation is not based on medical evidence and may interfere with disease control by immunomodulatory drugs. The present study was designed to help discuss the effect of DMT for MS on pregnancy and on disease course. PATIENTS AND METHODS: Retrospective data from 152 pregnancies of 132 women with MS were collected by the physician in charge of the case. All data were entered into a specific file for qualitative and quantitative statistical analysis. RESULTS: From the total group of patients, 89 pregnancies occurred without any exposure to MS drugs, while 61 pregnancies occurred with at least eight weeks of exposure to MS immunomodulatory drugs. The rate of obstetric and neonatal complications was similar in both groups, except for the newborn weight and height which was smaller for mothers receiving medications. Mothers' post-delivery relapse rate and EDSS scores in the follow-up period were significantly higher in the absence of treatment. CONCLUSION: It is possible that, with further such supportive data, international guidelines on MS treatment in young women who intend to get pregnant may need to be revised.
Authors: Yara D Fragoso; Tarso Adoni; Soniza V Alves-Leon; Nério D Azambuja; Amilton A Barreira; Joseph B B Brooks; Denise S D Carneiro; Margarete J Carvalho; Rinaldo Claudino; Elizabeth R Comini-Frota; Renan B Domingues; Alessandro Finkelzstejn; Paulo D Gama; Maria C B Giacomo; Sidney Gomes; Marcus V M Goncalves; Anderson K Grzesiuk; Damacio R Kaimen-Maciel; Maria F Mendes; Nivea M O Morales; Rogério R Morales; Andre Muniz; Regina M Papais-Alvarenga; Monica K F Parolin; Sonia B F Ribeiro; Heloisa H Ruocco; Fabio Siquineli; Elza D Tosta Journal: CNS Drugs Date: 2013-11 Impact factor: 5.749
Authors: Marta Giannini; Emilio Portaccio; Angelo Ghezzi; Bahia Hakiki; Luisa Pastò; Lorenzo Razzolini; Elisa Piscolla; Laura De Giglio; Carlo Pozzilli; Damiano Paolicelli; Maria Trojano; Maria Giovanna Marrosu; Francesco Patti; Loredana La Mantia; Gianluigi Mancardi; Claudio Solaro; Rocco Totaro; Maria Rosaria Tola; Giovanna De Luca; Alessandra Lugaresi; Lucia Moiola; Vittorio Martinelli; Giancarlo Comi; Maria Pia Amato Journal: BMC Neurol Date: 2012-10-22 Impact factor: 2.474